Mitogen-activated protein (MAP) Kinase/MAP kinase phosphatase regulation: Roles in cell growth, death, and cancer

被引:482
作者
Boutros, Tarek [1 ,2 ]
Chevet, Eric [1 ,3 ,4 ]
Metrakos, Peter [1 ]
机构
[1] McGill Univ, Dept Surg, Montreal, PQ H3A 1A1, Canada
[2] McGill Univ, Dept Anat & Cell Biol, Montreal, PQ H3A 1A1, Canada
[3] Inst Natl Sante & Rech Med, U889, Team Avenir, Bordeaux, France
[4] Univ Bordeaux 2, F-33076 Bordeaux, France
关键词
D O I
10.1124/pr.107.00106
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Mitogen-activated protein kinase dual-specificity phosphatase-1 (also called MKP-1, DUSP1, ERP, CL100, HVH1, PTPN10, and 3CH134) is a member of the threonine-tyrosine dual-specificity phosphatases, one of more than 100 protein tyrosine phosphatases. It was first identified approximately 20 years ago, and since that time extensive investigations into both mkp-1 mRNA and protein regulation and function in different cells, tissues, and organs have been conducted. However, no general review on the topic of MKP-1 exists. As the subject matter pertaining to MKP-1 encompasses many branches of the biomedical field, we focus on the role of this protein in cancer development and progression, highlighting the potential role of the mitogen-activated protein kinase (MAPK) family. Section II of this article elucidates the MAPK family cross-talk. Section III reviews the structure of the mkp-1 encoding gene, and the known mechanisms regulating the expression and activity of the protein. Section IV is an overview of the MAPK-specific dual-specificity phosphatases and their role in cancer. In sections V and VI, mkp-1 mRNA and protein are examined in relation to cancer biology, therapeutics, and clinical studies, including a discussion of the potential role of the MAPK family. We conclude by proposing an integrated scheme for MKP-1 and MAPKin cancer.
引用
收藏
页码:261 / 310
页数:50
相关论文
共 537 条
  • [1] ERK-8, a new member of the mitogen-activated protein kinase family
    Abe, MK
    Saelzler, MP
    Espinosa, R
    Kahle, KT
    Hershenson, MB
    Le Beau, MM
    Rosner, MR
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (19) : 16733 - 16743
  • [2] Abe MK, 1999, MOL CELL BIOL, V19, P1301
  • [3] Evaluation of glucocorticoid sensitivity in 697 pre-B acute lymphoblastic leukemia cells after overexpression or silencing of MAP kinase phosphatase-1
    Abrams, MT
    Robertson, NM
    Litwack, G
    Wickstrom, E
    [J]. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2005, 131 (06) : 347 - 354
  • [4] Positive and negative consequences of Fas/Fas ligand interactions in the antitumor response
    Abrams, SI
    [J]. FRONTIERS IN BIOSCIENCE-LANDMARK, 2005, 10 : 809 - 821
  • [5] Two co-existing mechanisms for nuclear import of MAP kinase: passive diffusion of a monomer and active transport of a dimer
    Adachi, M
    Fukuda, M
    Nishida, E
    [J]. EMBO JOURNAL, 1999, 18 (19) : 5347 - 5358
  • [6] The proteasome: A suitable antineoplastic target
    Adams, J
    [J]. NATURE REVIEWS CANCER, 2004, 4 (05) : 349 - 360
  • [7] Structure of human dual specificity protein phosphatase 23, VHZ, enzyme-substrate/product complex
    Agarwal, Rakhi
    Burley, Stephen K.
    Swaminathan, Subramanyam
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2008, 283 (14) : 8946 - 8953
  • [8] Modulation of the Ras/Raf/MEK/ERK pathway by Ca2+, and calmodulin
    Agell, N
    Bachs, O
    Rocamora, N
    Villalonga, P
    [J]. CELLULAR SIGNALLING, 2002, 14 (08) : 649 - 654
  • [9] Agre P, 1983, Invest New Drugs, V1, P33
  • [10] Downregulation of microRNAs-143 and-145 in B-cell malignancies
    Akao, Yukihiro
    Nakagawa, Yoshihito
    Kitade, Yukio
    Kinoshita, Tomohiro
    Naoe, Tomoki
    [J]. CANCER SCIENCE, 2007, 98 (12) : 1914 - 1920